|

A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension

RECRUITINGSponsored by Boryung Pharmaceutical Co., Ltd
Actively Recruiting
SponsorBoryung Pharmaceutical Co., Ltd
Started2023-07-26
Est. completion2025-10-21
Eligibility
Age19 Years+
Healthy vol.Accepted

Summary

The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension

Eligibility

Age: 19 Years+Healthy volunteers accepted
Inclusion Criteria:

* Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
* Those who voluntarily signed a written personal information agreement to participate in this clinical study.
* Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.

Exclusion Criteria:

* Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
* Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
* Those who are expected to need insulin prescription during the study period
* Pregnant women, breast-feeding women

Conditions3

DiabetesDiabetes MellitusHypertension

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.